The University of Nevada, Reno School of Medicine

​TEST Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis

Differentiate tyrosine kinase 2 (TYK2) inhibitors from Janus kinase (JAK) inhibitors 

Identify patients with moderate to severe psoriasis who may benefit from oral small molecule treatment 

Psoriasis is a chronic, immune-mediated inflammatory disease characterized by dysregulated IL-23/IL-17 axis signaling and keratinocyte hyperproliferation, resulting in well-demarcated erythematous plaques with silvery scale. Beyond cutaneous involvement, psoriasis has been linked to systemic inflammation contributing to increased risk of cardiometabolic and other inflammatory comorbidities.

This hub gathers the evidence, expert perspective, and practical insight shaping how psoriasis is understood and treated today, connecting advances in targeted therapy with the everyday decisions required to manage chronic inflammation and systemic risk.

TEST FC25: Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis

About

Learning Objectives

Intended Audience

Faculty

Accreditation Statement

Credit Designation Statement

Disclosures

TEST FC25: ​Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis

About

About

Learning Objectives

Learning Objectives

Intended Audience

Intended Audience

Faculty

Faculty

Accreditation Statement

Accreditation Statement

Credit Designation Statement

Credit Designation Statement

Disclosures

Disclosures

TEST FC25: Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis